MYD88 and metabolic dysfunction-associated steatotic liver disease: To explore the role of MyD88 in NAFLD-related liver cancer, SMAMyD88−/− and MyD88fl/fl mice were first treated with an intraperitoneal injection of 50 μg/g DEN (Sigma-Aldrich, St.